Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials by Aurélie Moreau et al.
REVIEW ARTICLE
published: 09 August 2012
doi: 10.3389/fimmu.2012.00218
Tolerogenic dendritic cells and negative vaccination in
transplantation: from rodents to clinical trials
Aurélie Moreau , Emilie Varey , Gaëlle Bériou , Marcelo Hill , Laurence Bouchet-Delbos ,
Mercedes Segovia and Maria-Cristina Cuturi*
ITUN INSERM 1064, CHU Hôtel-Dieu, Nantes, France
Edited by:
Stephen P. Cobbold, University of
Oxford, UK
Reviewed by:
Stephen P. Cobbold, University of
Oxford, UK
Paul J. Fairchild, University of
Oxford, UK
*Correspondence:
Maria-Cristina Cuturi, INSERM
S1064, CHU Hôtel-Dieu, 30 Bd Jean
Monnet, 44093 Nantes Cedex 1,
France.
e-mail: maria-cristina.cuturi@
univ-nantes.fr
The use of immunosuppressive (IS) drugs to treat transplant recipients has markedly
reduced the incidence of acute rejection and early graft loss. However, such treatments
have numerous adverse side effects and fail to prevent chronic allograft dysfunction. In
this context, therapies based on the adoptive transfer of regulatory cells are promising
strategies to induce indefinite transplant survival. The use of tolerogenic dendritic cells
(DC) has shown great potential, as preliminary experiments in rodents have demonstrated
that administration of tolerogenic DC prolongs graft survival. Recipient DC, Donor DC, or
Donor Ag-pulsed recipient DC have been used in preclinical studies and administration
of these cells with suboptimal immunosuppression increases their tolerogenic potential.
We have demonstrated that autologous unpulsed tolerogenic DC injected in the presence
of suboptimal immunosuppression are able to induce Ag-specific allograft tolerance. We
derived similar tolerogenic DC in different animal models (mice and non-human primates)
and confirmed their protective abilities in vitro and in vivo. The mechanisms involved in the
tolerance induced by autologous tolerogenic DC were also investigated. With the aim of
using autologous DC in kidney transplant patients, we have developed and characterized
tolerogenic monocyte-derived DC in humans. In this review, we will discuss the preclinical
studies and describe our recent results from the generation and characterization of
tolerogenic monocyte-derived DC in humans for a clinical application. We will also discuss
the limits and difficulties in translating preclinical experiments to theclinic.
Keywords: tolerogenic dendritic cells, transplantation, translational research, clinical trial, immune tolerance
INTRODUCTION
The success rates of transplant surgery have significantly
improved over the past fifty years. However, without treatment,
the development of an immune response against the donor organ
by the transplant patients leads to graft destruction. To block
this immunological response and protect the transplanted organs
from rejection, a range of general immunosuppressive drugs (IS)
is necessary. Unfortunately, the use of IS drugs induces numerous
adverse side effects, increasing the risks of infection and cancer
(Dantal et al., 1998). The aim of research in transplantation today
is to find an approach to induce long-term acceptance of trans-
plants in the presence of minimal IS drug exposure. Cell therapy
appears to be an innovative and promising strategy to address
these problems (Bluestone et al., 2007). A European project called
the “One Study” has been set up to test the efficacy of different
immunoregulatory cell products in organ transplant recipients.
In our center, tolerogenic dendritic cells (DC) will be injected into
humans in an attempt to achieve donor-specific tolerance.
TOLEROGENIC DC IN ANIMAL MODELS
DC are potent antigen-presenting cells (APC), able to induce
either immunity or tolerance. After a brief description of the dif-
ferent types of mouse DC present in vivo, we will describe how
tolerogenic DC can be derived in vitro in different animal mod-
els, and their efficacy in transplantation models. In the last part of
this section, we will discuss the mechanisms of tolerance induced
by TolDC.
DIFFERENT TYPES OF DC DESCRIBED in vivo IN MICE
DC are present in small numbers in vivo and are mainly localized
in the spleen and lymph nodes (LNs). DC are a heterogeneous
population of cells that can be classified into two main subsets:
conventional DC and plasmacytoid DC. Conventional DC can be
either resident or migratory cells.
Resident DC are present in the spleen, LNs and thymus. In
the steady state, these DC are immature and become mature in
the presence of danger signals. They can be divided into three
subsets: CD4+CD8−, CD8α+ (DEC205+), and double negative,
CD4−CD8−DC. They also differ in their methods of antigen (Ag)
presentation. For example, CD8α+ resident DC are able to cross-
present exogenous Ag on MHC Class I (den Haan et al., 2000).
Thus, they mainly activate CD8+ T cells and produce high lev-
els of IL-12, which leads to a type 1 response (Hochrein et al.,
2001; Reis e Sousa et al., 1997). On the contrary, CD4+ resident
DC present Ag on MHC Class II and mainly stimulate CD4+
T cells (Dudziak et al., 2007). In lymphoid organs, resident DC
capture and present Ags to T cells. In contrast, migratory DC cap-
ture Ags in peripheral tissues and then migrate to LN where they
present Ag to T cells. The most frequently described migratory
DC are Langerhans cells present in the epidermis, although other
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migratory DC are also localized in the dermis and intestine. An
inter-DC Ag transfer function was suggested by Allan et al. (Allan
et al., 2006). In this context, migratory DC would bring Ag to LN,
where resident CD8+ DC would efficiently present this Ag and
induce CTL priming.
Plasmacytoid DC on the other hand, are actors of the immune
response in the context of viral infections. These DC recognize
viral DNA and RNA via TLR (Toll-Like Receptors) 7 and TLR9.
Upon activation, plasmacytoid DC present Ag and produce high
amounts of type 1 interferons.
In contrast to the different subsets of DC previously described,
a last population of DC, called inflammatory DC (iDC), is not
thought to exist in the steady state but to be produced in vivo in
response to inflammation. A recent study by Cheong et al. showed
that inflammatory DC originate in LN from circulating mono-
cytes (Cheong et al., 2010b). Like the other DC, iDC are able
to cross-present Ag by MHC Class I and stimulate naive or Ag-
memory T cells (Cheong et al., 2010b). Interestingly, GM-CSF
is essential for the generation of these DC as mice deficient in
GM-CSF do not generate DC from monocytes in their spleen
(Shortman and Naik, 2007).
GENERATION OF TOLEROGENIC DC IN ANIMAL MODELS
The dogma described in the literature is that immature DC
are tolerogenic and mature DC are immunogenic (Probst et al.,
2003). However, some properties of mature cells, such as Ag pre-
sentation to T cells and in vivo migration to lymphoid organs,
are also found in certain tolerogenic DC (TolDC). Thus, TolDC
could be either immature, maturation resistant, or alternatively-
activated cells (Ezzelarab and Thomson, 2011).
In most protocols, mouse DC are derived from bone mar-
row (BM). The conventional cytokines used to derive DC from
precursors are GM-CSF and IL-4. However, a study performed
in mice in 2000 showed that DC generated with low doses of
GM-CSF in the absence of IL-4 have the properties of immature
tolerogenic DC. These cells have a high capacity for Ag cap-
ture/presentation and induce a low level of allogeneic T cell prolif-
eration. Furthermore, they are maturation-resistant and increase
graft survival after in vivo injection (Lutz et al., 2000). Various
DCmanipulations ex vivo have been described to generate TolDC.
For example, treatment of DC with Dexamethasone, VitaminD3,
IL-10, TGF-β, rapamycin, LPS, or gene transfer (Morelli and
Thomson, 2007) has been shown to increase their efficacy and
block the maturation process (see Table 1 for details).
Compared to the different types of DC described in vivo,
TolDC generated in vitro should be similar to inflammatory DC,
as these cells are not normally found in the steady state but are
present in vivo in a context of inflammation (Shortman and Naik,
2007). Furthermore, inflammatory DC need GM-CSF for their
differentiation and this cytokine is also essential for the in vitro
generation of TolDC.
While DC are derived from BM in rodents, monocytes are used
in humans. To compare the importance of the precursors in the
generation of tolerogenic DC, non-human primate models can
be used. In most studies, DC are derived from peripheral blood
monocytes. After CD14 positive selection, monocytes are cul-
tured with GM-CSF (800–1000U/ml) and IL-4 (500–1000 U/ml)
to obtain DC (O’Doherty et al., 1997; Barratt-Boyes et al., 2000;
Asiedu et al., 2002; Ashton-Chess and Blancho, 2005; Mortara
et al., 2006; Zahorchak et al., 2007). In parallel, two studies have
shown the possibility of deriving DC from CD34+ bone-marrow
precursors (Pinchuk et al., 1999; Ashton-Chess and Blancho,
2005). Using cynomolgus macaques, we compared the generation
of DC frommonocytes and from BM (either from total cells as for
rodents or from CD34+ precursors) (Moreau et al., 2008). Our
results showed that the DC phenotype and function vary accord-
ing to the origin of the precursors. As such, DC generated from
monocytes (MoDC) have a more homogeneous phenotype with
all cells expressing CD86. In BM derived DC, only half of the cells
are CD86 positive, regardless of whether the CD34 precursors are
isolated or not. However, neither MoDC nor BMDC express the
maturation marker CD83, suggesting that these cells are semi-
mature DC. In terms of their function, macaque MoDC induce
less proliferation of freshly isolated natural Tregs than their BM-
derived DC counterparts (Moreau et al., 2008). Another study
performed in our center compared the generation of baboon DC
from monocytes or from CD34+ BM precursors. The authors
also concluded that different DC were obtained depending on the
precursor cell-type (Ashton-Chess and Blancho, 2005).
EFFICACY OF TOLEROGENIC DC IN ANIMAL MODELS
In transplantation, DC present donor Ag to recipient T cells either
by the direct pathway, the indirect pathway or the semi-direct
pathway. By the direct allorecognition pathway, donor DC present
donor peptide/donor MHC molecules to T cells, this type of Ag
presentation is mainly associated with acute graft rejection. In
contrast, the indirect pathway is defined by the presentation of
donor peptide by recipient MHC molecules and is thought to
induce chronic rejection. In the semi-direct allorecognition path-
way, recipient DC present donor MHC molecules (transferred
from donor cells) to T cells (Herrera et al., 2004; Smyth et al.,
2006). In order to achieve donor-specific tolerance using DC
therapy in transplantation, both donor tolerogenic DC (direct
pathway) or recipient tolerogenic DC loaded with donor peptides
(indirect pathway) have been tested in animal models of trans-
plantation. The efficacy of these different types of DC has been
demonstrated in rodent models, as described in Table 1 (Morelli
and Thomson, 2007; Ezzelarab and Thomson, 2011).
Recently, Morelli’s group demonstrated that injected donor
DC are actually unable to directly regulate donor-specific T cells
in vivo in mice. In fact, after injection, donor tolerogenic DC die
quickly and the donor Ag is reprocessed and presented by the host
DC via the indirect pathway (Divito et al., 2010). In this context,
donor DC mediate their suppressive effects on T cells through
endogenous conventional DC from the recipient mouse (Wang
et al., 2012).
These results indicate that injected donor TolDC act as “donor
Ag transporting cells”, which could be related to the DST (donor
specific transfusion) protocol. DST, which consists in injecting
donor blood into the recipient before transplantation, is still used
in the clinic. Some studies have shown that DST improves graft
survival and function (Sharma et al., 1997; Marti et al., 2006).
In parallel, we demonstrated in a rat model of fully MHC-
mismatched cardiac allotransplantation that injection of unpulsed
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recipient DC the day before the transplant induces longer graft
survival than the injection of donor DC (Peche et al., 2005).
To improve the system and to create clinically applicable con-
ditions, recipient DC were then injected into rats treated with
a suboptimal dose of the IS drug, LF15-0195 (Beriou et al.,
2005). This deoxyspergualin analog is known to inhibit DC mat-
uration by blocking NF-κB activation (Yang et al., 2003). Both
recipient DC and LF15-0915 have a synergic effect and this co-
treatment induces tolerance to the allogeneic heart transplant in
90% of treated rats. We then investigated whether the tolerance
was donor-specific. To answer this question, tolerant rats received
syngeneic, donor or third-party skin grafts at 100 days post heart
transplantation. Only the third-party skin graft was rejected,
showing that the tolerance induced by recipient TolDC + LF
15-0195 was donor specific (Beriou et al., 2005).
To confirm the efficacy of cell therapy using recipient TolDC,
we generated TolDC in mice (Segovia et al., 2011) and in non-
human primates (Moreau et al., 2009). As previously shown in
rats, injection of mouse recipient TolDC associated with a tran-
sient anti-CD3 treatment prolonged graft survival in both skin
and pancreatic islet transplantation models (Segovia et al., in
preparation). In macaques, we showed that TolDC are able to
expand Treg in vitro (Moreau et al., 2008).
MECHANISMS OF ACTION OF TolDC
TolDC are thought to exert their actions using different mecha-
nisms. First, these cells can induce either T cell anergy or clonal
deletion. T cell anergy occurs when DC lacking costimulation
molecules interact with T cells. In the presence of Ag but with-
out costimulatory signals, T cells become anergic and lose their
ability to proliferate (Schwartz, 1997; Lechler et al., 2001). On
the other hand, TolDC can induce T cell apoptosis. One mecha-
nism described to induce this clonal deletion is an over-activation
of T cells, called AICD (Activation Induced Cell Death). The
Fas/Fas ligand pathway (Lu et al., 1997), but also expression of
IDO (indoleamine 2,3-dioxygenase) (Mellor et al., 2003) by DC,
leads to AICD in effector T cells. The T cells targeted by clonal
deletion are either naive or memory cells (Kenna et al., 2008).
Another major mechanism of action of TolDC is the gener-
ation/expansion of regulatory T cells. Some studies have shown
the ability of GM-CSF-derived DC to induce expansion of natural
CD4+CD25+FoxP3+ Treg (Yamazaki et al., 2003; Emmer et al.,
2006) whereas others have shown the ability of TolDC to generate
Treg from naive CD4+CD25− T cells (Fujita et al., 2007). In par-
allel, the generation of Tr1 by TolDC has also been demonstrated
(Wakkach et al., 2003). Molecules expressed by TolDC, such as
IDO or Galectin-1, have been shown or suggested respectively to
be involved in the generation/expansion of regulatory T cells (Hill
et al., 2007; Ilarregui et al., 2009). As the half-life of DC is short,
the generation/expansion of Treg is an important mechanism.
Indeed, Kendal et al. recently showed that Treg can maintain an
infectious tolerance by de novo generation of Foxp3+ Tregs from
naive CD4+ T cells (Kendal et al., 2011).
Besides the involvement of IDO expression by TolDC
described in the two previous paragraphs, TolDC have also been
shown to express tolerogenic markers such as HO-1 (Heme
Oxygenase-1) and EBI3 (Epstein-Barr virus-Induced gene 3).
Expression of HO-1 was demonstrated to correlate with DC mat-
uration state (Chauveau et al., 2005) in that immature tolerogenic
DC expressed high levels of HO-1, and this molecule enabled
tolerogenic DC to inhibit allogeneic T cell proliferation. In both
rats and macaques, blockade of HO-1 in TolDC impaired their
ability to suppress T cell proliferation in vitro. Furthermore,
in our model of tolerance to heart transplantation using both
recipient TolDC and LF15-0195, blockade of HO-1 prevented tol-
erance induction (Moreau et al., 2009). EBI3+, another marker
expressed by TolDC, also has a crucial role. In a rat cardiac
allotransplantation model developed in the laboratory using syn-
geneic TolDC, an increase in double-negative T cells (TCRαβ+,
CD3+, CD4−CD8− NKRP1−, DNT) was observed in the spleen
of tolerant mice. These DNT cells produced IFN-γ, which was
essential for the tolerance induction, as anti-IFN-γ treatment
of recipient mice led to the loss of tolerance induction (Hill
et al., 2011). To investigate how injection of TolDC mediates
IFN-γ production by DNT and tolerance induction, we identi-
fied the possible regulatory cytokines produced by TolDC. Our
results showed that TolDC express EBI3. By using anti-EBI3
antibody and EBI3 siRNA, we demonstrated that expression of
EBI3 by TolDC is essential for IFN-γ production by DNT cells.
Furthermore, in our in vivo model of tolerance induction using
TolDC, anti-EBI3 treatment of the recipient mice induced graft
rejection, highlighting the key role of EBI3 expressed by TolDC in
tolerance induction (Hill et al., 2011). It is important to note that
the cytokine IL-35 is made up of EBI3 and p35 subunits. It has
previously been demonstrated that IL-35 is secreted by regulatory
T cells (iTr35+ cells) and contributes to their regulatory function
(Collison et al., 2007; Niedbala et al., 2007; Collison et al., 2010;
Chaturvedi et al., 2011).
As we had proved the relevance of using unpulsed recipient
TolDC to induce donor-specific tolerance in several animal mod-
els, we wanted to understand the mechanisms of action of these
cells. In contrast to most studies using TolDC (donor TolDC or
donor-pulsed recipient TolDC), recipient TolDCwere injected the
day before transplantation (instead of one week before). After
injection, recipient cells migrated rapidly to the spleen and were
still detectable in this organ 15 days later (Peche et al., 2005).
In parallel, donor derived MHC ClassII+ cells (OX3+) from the
graft were present in the spleen 3–5 days post transplantation and
seemed to interact with the injected TolDC.We hypothesized that
injected recipient TolDC were able to process the donor Ag at this
stage. To reinforce this hypothesis, we depleted graft passenger
leukocytes (interstitial DC) from the donor hearts by administra-
tion of cyclophosphamide to the donor rat before transplantation.
In this context, treatment of recipient animals with unpulsed
recipient DC and LF15-0195 failed to induce any graft prolon-
gation (unpublished results). However, the effect of recipient
DC and LF15-0195 was rescued when donor splenic APC were
injected in this model. These results highlight the essential role of
graft passenger leukocytes in recipient TolDC therapy.
TOLEROGENIC DC IN HUMANS AND CLINICAL TRIALS
Studies performed in rodents ensured the characterization and
the efficient use of TolDC in vivo. The goal today is to trans-
fer this knowledge to humans in order to treat patients with
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tolerogenic DC. However, even though it is technically possible to
derive DC from BM in humans (Berger et al., 2009), the culture
of peripheral blood monocytes appears to be a reliable means to
generate DC in humans. As described above, we know from stud-
ies in non-human primates that the different origin of tolerogenic
DC in rodents and human can limit their comparison.
GENERATION OF HUMAN TolDC
Protocols of human MoDC generation are based on the knowl-
edge acquired in animals. In most cases, human MoDC are
obtained by culture of monocytes with GM-CSF and IL-4.
However, more recently, humanMoDC generated in the presence
of GM-CSF and without IL-4 were described to have tolerogenic
properties in vitro, like their counterparts in mice (Lutz et al.,
2000; Chitta et al., 2008). Furthermore, as in animalmodels, other
protocols have been reported to derive human tolerogenic DC
from monocytes in the presence of pharmacological agents such
as IL-10 or rapamycin (Morelli and Thomson, 2007; Gregori et al.,
2010; Turnquist et al., 2010; Ezzelarab and Thomson, 2011).
To generate human TolDC for clinical trials, we decided to
use a simple protocol. We derived human TolDC from mono-
cytes (0.5 million/ml) cultured in AIM V medium supplemented
with low-dose GM-CSF (100U/ml) for 6 days. In this protocol,
monocytes are enriched from leukapheresis of peripheral blood
by elutriation (purity around 90–95%). Elutriation is a purifica-
tion technique that separates cells based on their size and density
(Berger et al., 2005). This cell separation technique enriches
untouched monocytes in a closed and disposable system that is
adapted for GMP (Good Manufacturing Practice) facilities. The
advantages of using elutriation instead of bead selection are that
the cells are untouched and there is no risk of injecting extra com-
ponents (i.e., beads) to humans. The disadvantage of elutriation
is a lower degree of cell purity, although this is not a real problem
when autologous cells are injected. After one week of differentia-
tion, human TolDC are more than 90% MHC-II+ and less than
2% contaminated with T cells, B cells, or NK cells. These TolDC
are hypostimulatory and do not over-express CD80 or CD86
markers and remain CD83 negative after LPS/IFN-γ stimulation.
Furthermore, upon stimulation, TolDC secrete very low doses of
IL-12 but are able to produce IL-10. Interestingly, as we described
previously in rats (Hill et al., 2011), human TolDC also express the
tolerogenic marker EBI3 after stimulation. These results suggest
that our protocol generates tolerogenic DC that are semi-resistant
to maturation, which is essential to ensure that they will not
mature and become immunogenic once injected into patients.
USE OF HUMAN TolDC IN CLINICAL TRIALS
Even though clinical protocols of vaccination using immuno-
genic DC have been tested over the past 15 years to prevent
the development of tumors in cancer patients (Correale et al.,
2001; Redman et al., 2008), less is known about the potential
use of tolerogenic DC in the clinic. A first study published in
2001 demonstrated the feasibility and safety of injecting autolo-
gous immature TolDC in healthy volunteers (Dhodapkar et al.,
2001). In this study, immature DC were pulsed with peptides
and injected by the subcutaneous route into two volunteers.
Each individual received a single injection of 2 million cells. The
DC injections were well-tolerated without signs of toxicity and
no evidence of autoimmunity was detected. Injection of DC was
associated with Ag-specific inhibition of effector T cell function
and induction of Ag-specific CD8 Tregs in vivo (Dhodapkar et al.,
2001; Dhodapkar and Steinman, 2002). The first phase I clinical
trial using tolerogenic DC was reported recently in type 1 dia-
betic patients (Giannoukakis et al., 2011). Ten patients received
four intradermal injections of 10 million autologous DC. Three
patients received control DC generated in the presence of GM-
CSF and IL-4 and seven patients received immunosuppressive
DC generated in the presence of GM-CSF, IL-4, and antisense
oligonucleotides targeting CD40, CD80, and CD86 transcripts.
Use of tolerogenic DC generated with these antisense oligonu-
cleotides was shown previously by the same team to have a
preventive and curative effect on diabetes in NOD mice (Machen
et al., 2004). This Phase I study demonstrated that intradermal
injections of autologous TolDC (both control and immunosup-
pressive DC) are well-tolerated and safe in diabetic patients;
no adverse effects or toxicity was observed. Interestingly, the
authors observed a statistically significant increase in frequency of
B220+CD11c− lymphocytes in patients treated with autologous
TolDC (both control and immunosuppressive DC) during the
DC administration period compared to baseline (Giannoukakis
et al., 2011). Other clinical trials in autoimmune diseases, and
more specifically in rheumatoid arthritis (RA), will begin shortly.
The first one will be performed by R. Thomas’s team in Australia
(University of Queensland). BAY11-7082-treated DC loaded with
citrullinated peptides derived from candidate RA auto-antigens
will be used (Hilkens et al., 2010). Indeed, in a mouse model of
Ag-induced arthritis, the authors previously showed that injec-
tion of BAY11-7082 treated Ag-loaded DC suppressed DTH
(Delayed Type Hypersensitivity) reactions and arthritis (Martin
et al., 2007). BAY11-7082, aNFκB inhibitor, affects DC differen-
tiation, leading to a low expression of MHC Class II and CD40.
In vivo injection of BAY11-7082-treated DC prevents priming
of immunity and induces IL-10 producing CD4+Tregs (Martin
et al., 2003). In parallel, another clinical trial in RA will be per-
formed by CMU Hilkens and JD Isaacs in the UK (University of
Newcastle). In this case, autologous DC will be generated with
Dexamethasone and VitaminD3 and loaded with synovial fluid
(Hilkens et al., 2010).
So far there have been no reports of clinical trials using
TolDC in transplantation. As part of a European project, we will
test the safety of autologous monocyte-derived TolDC in kidney
transplant patients.
ADVANTAGES OF USING AUTOLOGOUS TolDC
In animal models of transplantation, most studies use donor
TolDC or recipient TolDC loaded with donor Ag. In contrast, we
have shown the efficacy of unpulsed recipient TolDC to induce
tolerance. In humans, the use of autologous TolDC is preferable
due to the safety and feasibility of applying this type of DC to a
clinic context.
In terms of safety, the major risk of donor TolDC injection
in transplantation is donor sensitization. Maturation of TolDC
after in vivo injection or the presence of a slight contaminant
cell product could lead to the development of sensitization of
the recipient to the donor Ag. In this case, priming or a higher
immune response against the graft could potentially occur at the
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time of transplantation. Furthermore, another risk of injecting
allogeneic cells is non-self recognition by the host immune sys-
tem. In this context, the injected cells may be deleted by recipient
NK cells (Yu et al., 2006).
In terms of clinical application in transplantation, the use of
autologous TolDC is compatible with both living and deceased
donor transplants. Autologous cell therapy could thus be applied
to all transplanted organs. Another advantage of using autologous
cell therapy is that the cell product could be prepared as soon as
the patient is waiting for a transplant and preserved frozen. At the
time of transplantation, the cells could be thawed and injected
without any preliminary preparations. The use of autologous
TolDC is all the more applicable to the clinic as neither the donor
nor the time of transplantation have to be planned in advance,
in accordance with the use of transplants from deceased donors.
Although the preparation and injection of autologous TolDC
in patients would be costly, cell therapy is considered as a promis-
ing approach. It leads to an induction of Ag-specific tolerance
without depleting an entire population of lymphocytes or block-
ing costimulation molecules. Like IS drugs, one could assume
that these efficient but large-scale treatments could potentially
induce side effects. Another cheaper alternative approach to
induce Ag-specific tolerance would be to deliver donor Ags
to quiescent conventional host DC in vivo. This technique was
shown to be feasible in mice using either CD205+ DC or DCIR2+
DC (Hawiger et al., 2001; Bonifaz et al., 2002, 2004). In this
second model, targeting of donor MHC molecules to DCIR2+
DC led to indefinite survival of MHC Class I mismatched skin
grafts (Tanriver et al., 2010). However, it seems that the effect
of Ag targeting to DC depends on their state of activation. For
example, some studies have shown that injection of Ag coupled
to DEC205 and anti-CD40 antibody or TLR ligands initiates
immune responses against the targeted Ag (Bonifaz et al., 2004;
Boscardin et al., 2006; Trumpfheller et al., 2008). So although this
technique targets DC, the induction of tolerance or immunity
will depend on whether the DC are immature or mature (Bonifaz
et al., 2004). The use of human anti-human DEC205 Ab in
vaccination was confirmed in human Ig-expressing transgenic
mice (Cheong et al., 2010a). This technique would be useful
on the strict condition that DC maturation can be inhibited,
to assure that the Ags target only immature DC in humans
(Shortman et al., 2009). In contrast, the first clinical trials with
injected TolDC described above have proven the safety and
absence of toxicity of using autologous DC in humans.
APPLICATION OF TolDC IN THE CLINIC
The cells that we described above were obtained from the blood
of healthy volunteers. For the clinical trial in kidney transplant
patients, TolDC will be generated using monocytes from patients
with chronic renal failure. Before the beginning of the clini-
cal trial, it is essential to validate our TolDC in these patients.
A comparative study of the generation of clinical grade TolDC
in healthy volunteers and in RA patients was reported prior to
a clinical trial ongoing in RA using autologous TolDC (Harry
et al., 2010). Their results showed that TolDC generated from
RA patients have a similar phenotype and in vitro function as
those generated from healthy controls (Harry et al., 2010). In
order to develop immunotherapy for multiple sclerosis, another
team described TolDC derived from relapsing-remitting multiple
sclerosis (RR-MS) patients. Their results showed that TolDC gen-
erated with VitaminD3 from RR-MS patients and from healthy
controls display a similar differentiation and function (Raiotach-
Regue et al., 2012). As well as the origin of the samples (volunteers
versus patients), other parameters have to be taken into con-
sideration for the GMP preparation of TolDC, as described in
Table 2.
Prior to TolDC injection, different parameters which could
influence immunogenicity and survival of the injected cells also
have to be defined, as described in Table 3. One of these is the
route of DC administration. Experiments performed in mice
have shown that intravenous injection of Dex/LPS-treated BMDC
prolongs cardiac transplant survival whereas subcutaneous injec-
tion of the same Dex/LPS-treated BMDC does not increase graft
survival (Emmer et al., 2006). In parallel, our experiments in
macaques show that intradermal injection of autologous TolDC
prime an immune response while intravenous injection favors a
tolerogenic role of these TolDC (unpublished results). A study
also performed in monkeys confirmed the fact that intravenous
injection of TolDC is well-tolerated (Zahorchak et al., 2007).
Another parameter is the potential treatment associated with
the cell injection, such as IS drugs. These drugs could either
potentiate or inhibit the effect of TolDC in vivo. For the clinical
Table 2 | DC preparation conditions.
Parameters of
DC preparation
Controls to perform
Optimal cell
culture conditions
– patients sample
– adequate cytokines and medium
Clinical grade
reagents
– GMP grade cytokines and medium
– closed systems as bags
GMP facility – controlled room temperature/pressure
– standardization and quality controls of the protocols
– allowed and trained technicians
BASIC RULE = USE THE SIMPLEST PROTOCOL
Table 3 | Parameters of DC injection.
Parameters of DC
injections
Questions to answer before clinical trials
Origin of DC – donor DC
– donor pulsed recipient DC
– unpulsed recipient DC
Number of injections – single
– multiple
Time of DC injections – Prior transplantation (day-7 or day-1)
– Peri-transplantation
– Post transplantation
Amount of cells
administrated
related to the number of injections
Route of cell
administration
– Intradermal or subcutaneous: inflammatory way
– Intravenous: tolerogenic way
Associated
treatments
e.g., Immunosuppressive drugs
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trial in kidney transplantation, cell therapy will be performed
in patients treated with several IS drugs. Previous studies have
determined the interaction between DC therapy and IS. Indeed,
our experiments in a model of transplantation have shown that
treatment of rodents with rapamycin or cyclosporin A does not
improve the TolDC effect. This is different from the injection of
allo-Ag pulsed RAPA-DC in mice that promoted indefinite graft
survival when treated with low doses of rapamycin at the time
of transplantation (Turnquist et al., 2007). As regards human
TolDC, some in vitro studies have shown that rapamycin increases
CCR7 expression, which is necessary for TolDCmigration to lym-
phoid organs (Sordi et al., 2006). Other IS, such as calcineurin
inhibitors, including cyclosporin A or tacrolimus, block MHC-
restricted Ag processing pathways in mouse BMDC in vitro (Lee
et al., 2005). In the context of the One Study clinical trial, the
patients will receive three IS in combination with the cell therapy:
MMF (Mycophenolate mofetil), Tacrolimus and Prednisolone.
From a safety point of view, it is necessary to validate that
the TolDC will not interfere with the function of these IS. To
answer this question, graft survival after injection of each IS with
and without TolDC will be monitored in our mouse skin graft
model. So far, we have observed that injection of MMF induces
a prolongation of graft survival and injection of TolDC does
not impair this effect. In fact, a slight increase in graft survival
was detected (Segovia et al., in preparation). Similar experiments
using the two other IS associated or not with DC therapy are
ongoing. The combination of three IS in the presence or absence
of cell therapy will be also tested.
CONCLUSION
Cell therapy, e.g., TolDC, is currently considered as an attractive
approach to minimize the use of IS in transplantation. Studies
performed in rodent models have demonstrated the feasibility
and efficacy of TolDC for the induction of tolerance in transplan-
tation. In parallel, protocols to generate human TolDC in vitro
have been defined but most have not yet been tested in vivo.
New pre-clinical tools, such as humanized mice or non-human
primates, have emerged and will be used to help translate the
research findings from animal models to clinical application in
humans.
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